MedTrace Logo

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

NCT03971929 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-10-18

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.

Conditions

Interventions

DRUG

SHR0532

once daily(QD) for 4weeks

DRUG

SHR placebo

once daily(QD) for 4weeks

DRUG

Hydrochlorothiazide 25 mg

once daily(QD) for 4weeks

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2020-09-03
Completion
2020-09-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971929 on ClinicalTrials.gov